0001193125-21-361060.txt : 20211217 0001193125-21-361060.hdr.sgml : 20211217 20211217160203 ACCESSION NUMBER: 0001193125-21-361060 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20211215 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211217 DATE AS OF CHANGE: 20211217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lyell Immunopharma, Inc. CENTRAL INDEX KEY: 0001806952 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 833006753 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40502 FILM NUMBER: 211501444 BUSINESS ADDRESS: STREET 1: 201 HASKINS WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650 695-0677 MAIL ADDRESS: STREET 1: 201 HASKINS WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 d262325d8k.htm 8-K 8-K
false 0001806952 0001806952 2021-12-15 2021-12-15

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 15, 2021

 

 

Lyell Immunopharma, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-40502   83-3006753

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

201 Haskins Way

South San Francisco, California

   94080
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: 650 695-0677

(Former Name or Former Address, if Changed Since Last Report)

Not Applicable

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   LYEL   NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 1.01

Entry into a Material Definitive Agreement.

On December 16, 2021, Lyell Immunopharma, Inc. (“Lyell” or the “Company”) entered into a Second Amendment to Collaboration and License Agreement (the “Collaboration Amendment”) with GlaxoSmithKline Intellectual Property (No.5) Limited and Glaxo Group Limited (together “GSK”). The Collaboration Amendment amends the terms of that certain Collaboration and License Agreement by and between the Company and GSK, dated as of May 23, 2019 (as amended, the “GSK Agreement”). Pursuant to the Collaboration Amendment, among other things, Lyell will manufacture the NY-ESO-1 + Epi-R TCR cell therapy product candidate for an initial planned Phase 1 clinical trial (“Epi-R Trial”) at Lyell’s manufacturing facility in Bothell, Washington. GSK will conduct the Epi-R Trial under its First Time in Humans Master Protocol for NY-ESO-1 (“FTIH Protocol”) pursuant to a clinical plan agreed to by Lyell and GSK. Lyell is responsible for submitting the initial new drug application (“IND”) for this product candidate with the U.S. Food and Drug Administration (“FDA”), and GSK is responsible for filing its updated FTIH Protocol and for regulatory interactions with FDA related to that protocol. Each party bears its own costs associated with its responsibilities under the GSK Agreement. The Collaboration Amendment further specifies that Lyell is eligible (i) to receive milestone payments for any use of an Anti-Exhaustion Component in connection with a collaboration target, whether or not there was a specific research program and (ii) for one set of milestone and royalty payments with respect to a collaboration target, even if the approved product uses more than one Anti-Exhaustion Component. The Collaboration Amendment also modifies the scope of license grants in the GSK Agreement to conform to the modified responsibilities under the Collaboration Amendment and specifies that Lyell owns improvements to the Epi-R and Gen-R technologies. Glaxo Group Limited remains a significant stockholder of the Company.

The foregoing description of the Collaboration Amendment does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Collaboration Amendment, a redacted copy of which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the fiscal year ending December 31, 2021.

 

Item 8.01

Other Events.

On December 15, 2021, Lyell issued a press release announcing cGMP qualification of its LyFE manufacturing facility located in Bothell, Washington. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

On December 16, 2021, Lyell issued a press release announcing clearance by the U.S. Food and Drug Administration of its Investigational New Drug application for LYL797, which is a novel, ROR1-targeted CAR T-cell product that incorporates genetic and epigenetic reprogramming technologies, Gen-R and Epi-R, to potentially overcome barriers of CAR T-cell therapies in solid tumors. The Phase 1 clinical trial is designed to evaluate the safety and anti-tumor activity of LYL797 in patients with ROR1+ triple negative breast cancer or non-small cell lung cancer. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.2 and is incorporated herein by reference.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

Number

   

Description

99.1    Press release dated December 15, 2021
99.2    Press release dated December 16, 2021
104    Cover page interactive data file (embedded within the Inline XBRL document)

Forward Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this Current Report on Form 8-K include, but are not limited to, statements regarding: anticipated activities by Lyell and GSK under the

Collaboration Amendment; the potential receipt of milestone and royalty payments by the Company under the Collaboration Amendment; the planned submission of an IND to the FDA and other regulatory activity contemplated by the Collaboration Amendment; anticipated manufacturing and clinical trial activity under the Collaboration Amendment, including with respect to the planned Epi-R Trial; and other statements that are not historical fact. These statements are based on Lyell’s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: the effects of the evolving COVID-19 pandemic; Lyell’s ability to submit planned INDs on the anticipated timing or at all; the initiation of the planned Epi-R Trial and enrollment of patients in that trial; Lyell’s ability to manufacture and supply product candidate for planned Epi-R Trial; the preclinical profiles of Lyell’s product candidates not translating in clinical trials; the potential for results from clinical trials to differ from preclinical, early clinical, preliminary or expected results; significant adverse events, toxicities or other undesirable side effects associated with Lyell’s product candidates; the significant uncertainty associated with Lyell’s product candidates ever receiving any regulatory approvals; Lyell’s ability to maintain the GSK Agreement with GSK, including the risks that GSK may fail to meet its obligations under the GSK Agreement or may fail to apply sufficient efforts at developing and commercializing products under the GSK Agreement; Lyell’s ability to obtain, maintain or protect intellectual property rights related to its product candidates; implementation of Lyell’s strategic plans for its business and product candidates; the sufficiency of Lyell’s capital resources and need for additional capital to achieve its goals; and other risks, including those described under the heading “Risk Factors” in Lyell’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 and in Lyell’s future reports to be filed with the SEC. Forward-looking statements contained in this Current Report on Form 8-K are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

      Lyell Immunopharma, Inc.
Date: December 17, 2021     By:  

/s/ Heather Turner

     

Heather Turner

Chief General Counsel

 EX-99.1 2 d262325dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Lyell Immunopharma Announces cGMP Qualification of LyFE™ Manufacturing Center in Advance of Initiating Clinical Programs

 

  •  

Lyell’s cGMP-compliant manufacturing facility, is designed to produce cell products at scale for upcoming clinical trials across its CAR, TIL and TCR programs

 

  •  

LyFE Manufacturing Center integrates digital data analytics into processes for real-time production monitoring and optimization

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 — Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, announced today that its LyFE Manufacturing Center in Bothell, Washington has been commissioned and qualified in compliance with the U.S. Food and Drug Administration’s (FDA’s) Current Good Manufacturing Practices (cGMP).

The cGMP qualification confirms Lyell has the proper design, monitoring and control of its manufacturing facility. Since becoming operational in April 2021, the LyFE Center has completed successful engineering runs at scale in support of the Company’s planned upcoming clinical trials.

“We are advantageously positioned with qualified manufacturing infrastructure that we own and control to support consistent and reliable manufacture of cell products for our upcoming clinical trials,” said Liz Homans, Chief Executive Officer of Lyell. “We believe that combining cGMP manufacturing with our deep understanding of T-cell biology will help us achieve our vision of curing patients with solid tumors.”

With 70,000 square feet of space, the LyFE Manufacturing Center provides several key capabilities for cell therapy manufacturing. The facility utilizes electronic systems with advanced data and analytics for real-time feedback, batch monitoring and process optimization. To support its digital manufacturing capabilities, Lyell collaborates with Amazon Web Services (AWS). The LyFE Manufacturing Center is one of the first cell therapy manufacturing facilities to benefit from AWS’s extensive experience with cloud computing, Internet of Things (IoT) and advanced analytics.

“Lyell is dedicated to developing safe and effective cell therapies for patients by investing in innovative operations and technology, including our LyFE Manufacturing Center that is designed to support a broad pipeline and is now qualified to support cGMP manufacturing standards,” said Stephen Hill, Chief Operating Officer of Lyell. “Integrating digital systems into our manufacturing operations means quicker access to data, leading to faster recognition and implementation of process improvements.”

About Lyell Immunopharma, Inc.

Lyell is a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. The Company focuses on addressing what it believes are the primary barriers that limit consistent, reliable, and curative responses to adoptive T-cell therapy: T-cell exhaustion and lack of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes. Lyell is based in South San Francisco, California and Seattle and Bothell, Washington. To learn more, please visit www.Lyell.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: Lyell’s ability to produce cell products at scale for upcoming clinical trials across the Company’s

CAR, TIL and TCR programs; the integration of digital systems into our manufacturing operations and whether such integration will result in quicker access to data and faster recognition and implementation of process improvements; Lyell’s ownership and control of manufacturing infrastructure to support consistent and reliable manufacture of cell products for upcoming clinical trials; Lyell’s vision of curing patients with solid tumors; the therapeutic potential of Lyell’s product candidates; and other statements that are not historical fact. These statements are based on Lyell’s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: the effects of the evolving COVID-19 pandemic; Lyell’s ability to submit planned INDs on the anticipated timing or at all; initiation of planned clinical trials and enrollment of patients in its future clinical trials; Lyell’s ability to manufacture and supply its product candidates for its future clinical trials; the preclinical profiles of Lyell’s product candidates not translating in clinical trials; the potential for results from clinical trials to differ from preclinical, early clinical, preliminary or expected results; significant adverse events, toxicities or other undesirable side effects associated with Lyell’s product candidates; the significant uncertainty associated with Lyell’s product candidates ever receiving any regulatory approvals; Lyell’s ability to obtain, maintain, or protect intellectual property rights related to its product candidates; implementation of Lyell’s strategic plans for its business and product candidates; the sufficiency of Lyell’s capital resources and need for additional capital to achieve its goals; and other risks, including those described under the heading “Risk Factors” in Lyell’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 and Lyell’s future reports to be filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law.

Contact:

Ellen Rose

Vice President, Communications and Investor Relations

erose@lyell.com

EX-99.2 3 d262325dex992.htm EX-99.2 EX-99.2

Exhibit 99.2

 

LOGO

Lyell Immunopharma Announces FDA Clearance of its IND for LYL797, a CAR T-Cell Therapy Incorporating Novel Reprogramming Technologies for Solid Tumors

 

  •  

Expects to begin screening patients for the Phase 1 clinical trial by the end of the first quarter; initial data presentation expected in 2023

 

  •  

ROR1-targeted CAR T-cell therapy designed to overcome T-cell exhaustion and promote durable stemness incorporates Lyell’s novel genetic and epigenetic reprogramming technologies, Gen-R™ and Epi-R™

 

  •  

LYL797 targets ROR1, a highly expressed cell surface antigen present on many aggressive solid tumors

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2021 — Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for LYL797, Lyell’s first therapeutic candidate incorporating T-cell reprogramming technologies for the treatment of solid tumors. LYL797 is an investigational chimeric antigen receptor (CAR) T-cell therapy for patients with receptor tyrosine kinase-like orphan receptor 1-positive (ROR1+) solid tumors. LYL797 incorporates two Lyell technologies designed to address major barriers to successful Adoptive Cell Therapy (ACT): Gen-R, a genetic reprogramming technology that endows T cells with the ability to resist exhaustion, and Epi-R, an epigenetic reprogramming technology that creates populations of T cells with the properties of durable stemness. Durable stemness is the quality that enables T cells to self-renew, proliferate and persist, and create daughter cells with anti-tumor functionality. Lyell expects to begin screening patients with relapsed/refractory triple-negative breast cancer (TNBC) who have failed at least two lines of therapy by the end of the first quarter for the Phase 1 dose escalation phase of the trial and plans to expand the trial to include patients with non-small cell lung cancer (NSCLC) when a recommended dose is determined.

“Lyell is applying our understanding of T-cell biology to address what we believe are the primary barriers to consistently effective cell therapies for difficult to treat solid tumors,” said Liz Homans, Chief Executive Officer of Lyell. “Submission and clearance of our first IND is an important milestone for Lyell, and we remain on track to generate data for LYL797 in 2022 and plan to share initial data when we have a meaningful number of patients and an indication of clinical effect, which we expect to occur in 2023. We also remain on track to submit three additional INDs for our TIL and partnered TCR programs by the end of 2022.”

“This is the first time the FDA has cleared an IND that includes a specific genetic modification to address T-cell exhaustion, a phenomenon that is recognized as being a major barrier to the eradication of tumors by T cells,” stated Rick Klausner, MD, Chair of Lyell’s Board of Directors. “We look forward to testing this first-generation technology platform in the clinic, thus specifically addressing the question of exhaustion as a barrier to successful cell therapy in solid tumors.”

“While CAR T-cell therapies have proven effective in hematologic malignancies, patients with solid tumors have seen limited benefit from these approaches due to a tumor microenvironment that leads to T-cell exhaustion and a loss of durable stemness,” said Tina Albertson, MD, PhD, Chief Medical Officer and Head of Development of Lyell. “LYL797 is the first program to clinically evaluate our two T cell reprogramming technologies which are designed to overcome these barriers, with the goal of developing more effective therapies for patients with solid tumor cancers.”

Phase 1 Trial Design

The Phase 1 clinical trial is designed to evaluate the safety and anti-tumor activity of LYL797 in patients with ROR1+ TNBC or NSCLC.

The trial is an open label, dose escalation and expansion trial in patients with relapsed/refractory TNBC or NSCLC who have failed at least two lines of therapy. Once a dose is identified during dose escalation in TNBC, up to 15 patients with TNBC and 15 patients with NSCLC are expected to be enrolled at the recommended dose. The primary endpoint of this Phase 1 trial is safety and tolerability of LYL797. Secondary endpoints include clinical activity based on the evaluation of antitumor activity as evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) criteria and characterization of the pharmacokinetic profile of LYL797. Exploratory biomarkers of T-cell function – exhaustion and stemness – will also be assessed.

About TNBC and NSCLC

Breast cancer is the second most common cancer in American women. Approximately 10-15% of patients with breast cancer have TNBC and triple negative status tends to be more common in women who are younger than age 40, who are African American, or who have a BRCA1 mutation. In the United States, approximately 135,000 women suffered from TNBC in 2017. TNBCs present a high tendency to metastasize, and patients are at a higher risk to relapse compared to other types of breast cancers. TNBCs differ from other types of invasive breast cancer in that they grow and spread faster, have limited treatment options, and a worse prognosis. Once TNBC has spread to other parts of the body, the 5-year survival rate is only 11.5%. ROR1 is overexpressed in approximately 60% of patients with TNBC and ROR1 expression is correlated with poorer outcomes.

Lung cancer is the second most common cancer and is the leading cause of cancer mortality worldwide. NSCLC accounts for 84% of all lung cancers. ROR1 is overexpressed in approximately 40% of the patients with NSCLC. For people with localized NSCLC, the overall 5-year survival rate is ~60%. For regional NSCLC, the 5-year survival rate is ~35%. Based on current data, when NSCLC metastasizes, the 5-year survival rate is 6%.

About LYL797

LYL797 is a novel, ROR1-targeted CAR T-cell product that incorporates genetic and epigenetic reprogramming technologies, Gen-R and Epi-R, to overcome barriers of CAR T-cell therapies in solid tumors. Gen-R is an ex vivo genetic reprogramming technology that engineers CAR T cells to overexpress c-Jun. Dysregulation of activator protein 1 (AP-1) has been implicated in CAR T-cell exhaustion, and studies have demonstrated that overexpression of c-Jun renders CAR T cells less susceptible to exhaustion through the AP-1 pathway, enhancing both anti-tumor efficacy and persistence in preclinical models of hematologic and solid tumors. Epi-R is a proprietary technology that is designed to produce populations of T cells which have the properties of durable stemness – the quality that enables T cells to self-renew, proliferate and persist, and create daughter cells with anti-tumor functionality.

Preclinical in vitro and in vivo experiments of LYL797 against ROR1+ solid tumors have demonstrated that LYL797 maintains stem-like phenotypes and can resist exhaustion while inhibiting tumor growth in models of tumor cells expressing ROR1.

About Lyell Immunopharma, Inc.

Lyell is a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. The Company focuses on addressing what it believes are the primary barriers that limit consistent, reliable, and curative responses to adoptive T-cell therapy: T-cell exhaustion and lack of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes. Lyell is based in South San Francisco, California and Seattle and Bothell, Washington. To learn more, please visit www.Lyell.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: Lyell’s expectation to begin screening patients for the Phase 1 clinical trial and the timing thereof and to present initial data and the timing thereof; LYL797 and its ability to overcome T-cell exhaustion and promote durable stemness; Lyell’s plans to screen patients with relapsed/refractory triple-negative breast cancer (TNBC) who have failed at least two lines of therapy by the end of the first quarter for the Phase 1 dose escalation phase of the trial and to expand the trial to include patients with non-small cell lung cancer (NSCLC) when a recommended dose is determined; Lyell’s plans to submit three additional INDs for our TIL and partnered TCR programs and the timing thereof; Lyell’s vision of curing patients with solid tumors; the therapeutic potential of Lyell’s product candidates; and other statements that are not historical fact. These statements are based on Lyell’s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: the effects of the evolving COVID-19 pandemic; Lyell’s ability to submit planned INDs on the anticipated timing or at all; initiation of planned clinical trials and enrollment of patients in its future clinical trials; Lyell’s ability to manufacture and supply its product candidates for its future clinical trials; the preclinical profiles of Lyell’s product candidates not translating in clinical trials; the potential for results from clinical trials to differ from preclinical, early clinical, preliminary or expected results; significant adverse events, toxicities or other undesirable side effects associated with Lyell’s product candidates; the significant uncertainty associated with Lyell’s product candidates ever receiving any regulatory approvals; Lyell’s ability to obtain, maintain, or protect intellectual property rights related to its product candidates; implementation of Lyell’s strategic plans for its business and product candidates; the sufficiency of Lyell’s capital resources and need for additional capital to achieve its goals; and other risks, including those described under the heading “Risk Factors” in Lyell’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 and Lyell’s future reports to be filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law.

Contact:

Ellen Rose

Vice President, Communications and Investor Relations

erose@lyell.com

EX-101.SCH 4 lyel-20211215.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 lyel-20211215_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 6 lyel-20211215_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g262325g1217150858043.jpg GRAPHIC begin 644 g262325g1217150858043.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBJ-Y>B M(M'&Z(57=)*Y^6)?4^_M45*B@KO_ (<:5RS+<)$P3EI#T1>3_P#6I )GY=A& M/[J\G\ZYI]:G==FD0';(>+J92S2GU5>I^IP*:GAC4-2;S-5U.X*'_ED'_H.! M51I2>M5V\DD<#_ $ -9,/@_181 M_P >N\^K.:=+X1T:4<6QC8=&CD8$?K5>RHO_ (8:J8K?E7_@3_R--K"#^#?$ M?6-RO_UJC*WUMRCBYC'\+X5_S'!K#DT36M,_>:5J;SH/^6%P<_D>GZ5-IOBD M/FGX;?>F...M+DK1Y7Y[?)_\,;=O>17. M57*R+]Z-AAA5BJMU9I=!75MDJ\I(O4?XBF6=X[R-;7("7"?DX]16,:TX35.M MUV?1^7D_SZ=CL<4US1+M%%%=1F%%%% !1110!4U*^33[)YW8 ]%STS7-002Z MK''<3H7MW;-O;MQY[=Y'_P!GV]/KS8U:(ZYXCATP_P#'K;+YMS[^B_CQ^1KH M+>)=YFP!D;4']U165)-S=5^B\EU?JW^"\SGJKVS]G]E;^;_R7Y[[$=K9162- M+(P:4C,DK<<#T] /2K$-Q#<(7@ECE4'!*,&&?PJGKW_(NZG_ ->DO_H!KCOA M 2WA:\)))^VMU_W$K;S-HQ459'H-%%%(H*HZEI5KJD.R=,.OW)!]Y3_GM5ZB MFFUJB9PC-GV\1AMXXF[L96O>( M+'PY91W=^9!$\@B'EKDY()_H:T;>=+FVBN(\[)4#KD&ZA_ MR$;G_KJW\Z*KE0CZ'T$;X=2OBA5PGQ.L M;O\ L>#6+"66.:Q<%]C$90D<_@/WT8+@?PL.&'YYK3Z5YG\/+F70O$.J>$[MC\CF6W)[^N/JN#^ M!KH_B!KG]B>%9S&V+FZ_<0XZY/4_@,_I3MJ!S^@7$WBOXBWVJB9_[,TX>7" MQ"L>0#_Z$WY5'=ZYK?C?7)]+\/SFTTRW.V:Z'\7X^_85I6.E2>%_A5>!04O' MM'FE/<.R_P!!@?A7,^!?$EUHOAX0VOA^YNA)*SM/'T8]/TQ3 W/^%6LJ^8GB M"^%SUW$\9I-&\0:QX9\00^'_ !+)YT,^!;7?KV'/IGCVJW_PGNJ?]"M?5S?C M+4M4\4V-M$GAR\MYX)MZRD9P,H&]\7_\ D5;3_K]7_P! >NTT;_D! MZ?\ ]>T?_H(K@_BB\DG@72Y)E*RM<1,X/4,8VS7>:-_R ]/_ .O:/_T$4N@' MS+J'_(1N?^NK?SHHU#_D(W/_ %U;^=%6(]^L"8-'O[=1\UG-O ]D;_!/UKJ% M8.BNIRK#(/J*PKA!I^O>[&U_0'H?Y _G5S27,*R:=*3YEL<(3_%'_"? MRX_"N'"R^.F]XM_<]5^#M\A27+*+Z-6^:_SW':]_R+NI_P#7I+_Z :XKX131 M1^%KL/(BDWK<,P'\"5WUY;+>V-Q:NQ59XFC)'4 C']:X-?A)IJ A-2NU!.<# MBNM;%'??:K?_ )[Q?]]B@7,#$ 31DGH PK@_^%3V'_04O/SJQI_PSL=/U&VO M$U*[=H)5E"L>#M.<'\J- ,_XD6DND:KI?BRR7]Y;R".?'<=L_49'Y56DN8_' MOQ%LD@/F:5IL0F8]F)P?YX'X&NM\?75G:^"]0^V ,LL?EQIW+G[N/H>?PK.^ M&&A?V3X86[E3%Q?$2G/4)_"/YG\:?0#KK^SCU#3KFRE_U<\31M]",5YIX(US M_A$KZZ\,:X?(VREH)6^Z<]L^AX(^M>GSS1VT$D\K!8XU+,Q[ 5B7^AZ7XOTN M";4+(JSIN1LXD0'IS26UR>98/&/SKH?#_ (,T?PXWFVD)>X(P9I3N M;\/2C0HY_P"+_P#R*MI_U^K_ .@/7::-_P @/3_^O:/_ -!%4O$WANW\4:?% M9W,KQ)'*)04ZD@$?UK5M;=;6SAME)*Q1K&">I &*.@'R[J'_ "$;G_KJW\Z* M]DF^$>E33O*U[<9=BQX'>BJYD([R\M4O+9H7[]#Z'UK& GD95!"ZE:#"Y/$J M>E=!5'4-/^UA9(G\NXCY1_Z&N*M2DIJM2^):-=UV]>W_ 2GRR@X3V_)]Q]C M?Q7T65RDB\/&WWE-6ZYQ]EQ*M#5+VQ^74;-F4? M\MX!N7ZD=JWIU(U%=?=U1S^T=/2IMW6W_ -FN-\2:%XFFUH:KH6K"/\ =B,V MTG"X'IV/-=#%KNF3*K"\B7/3>=I_6I6U;3E&3?6__?P5H6JM-JZDOO.%C\$Z M_P"(-1@N/%>H(]K =RVT1^]^7'X]:]$ 6- J@*BC X %94_B*SCC=HM\VS[ MS*,*OU8X K$9]6\5/Y<3FTTW.))5!^8>BD_>^O2J47+7H85,7"/NP]Z3V2+U MS<#Q'?\ ]G6Q)T^!@UU,.DA'(0?UK6NW:5A96_!8?O&'\"_XU%:016EJMCI< M86-.#(>0#W/^TU7H($MTVKDD\LQZL?4US5I>W_=T_AZO_+UZOIZG1AZ4J=ZE M36;_ *2]%^.X]$$<:HN=J@ 9-.HHK5*RLBPHHHI@%%%% !1110!#<6T%W%Y5 MQ$LB=<,.A]1Z&L[^RKJV_P"0=J4L:#I#.OFK^!/S#\Z**&[*Y$J<9/7_ "_( MS;U-60?Z3:Z-._J8F_KFJL=O=2CG^S;4_P!Z"R#L/Q9OZ445Q_6:B;U_!'+" MA"<[2_-FI;Z';3.LURTM](O*FZ?*J?9 -HK8^S[P!*Q91T11M7\J**UA*5;^ G([_UV.V-*%'^&K?UW)@ H 4 = *6BBMP"BBB@ HHHH **** /_9 end XML 8 d262325d8k_htm.xml IDEA: XBRL DOCUMENT 0001806952 2021-12-15 2021-12-15 false 0001806952 8-K 2021-12-15 Lyell Immunopharma, Inc. DE 001-40502 83-3006753 201 Haskins Way South San Francisco CA 94080 650 695-0677 false false false false Common Stock, $0.0001 par value per share LYEL NASDAQ true false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Dec. 15, 2021
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001806952
Document Type 8-K
Document Period End Date Dec. 15, 2021
Entity Registrant Name Lyell Immunopharma, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-40502
Entity Tax Identification Number 83-3006753
Entity Address, Address Line One 201 Haskins Way
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code 650
Local Phone Number 695-0677
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol LYEL
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d262325d8k.htm d262325dex991.htm d262325dex992.htm lyel-20211215.xsd lyel-20211215_lab.xml lyel-20211215_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d262325d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d262325d8k.htm" ] }, "labelLink": { "local": [ "lyel-20211215_lab.xml" ] }, "presentationLink": { "local": [ "lyel-20211215_pre.xml" ] }, "schema": { "local": [ "lyel-20211215.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "lyel", "nsuri": "http://lyell.com/20211215", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d262325d8k.htm", "contextRef": "duration_2021-12-15_to_2021-12-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d262325d8k.htm", "contextRef": "duration_2021-12-15_to_2021-12-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 16 0001193125-21-361060-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-361060-xbrl.zip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end